Drugs that contain Tapentadol Hydrochloride

1. List of Nucynta drug patents

NUCYNTA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(9 months ago)

US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(2 years from now)

Do you want to check out NUCYNTA patents from before 2022?

Market Authorisation Date: 20 November, 2008

Treatment: Management of moderate to severe acute pain; Relief of moderate to severe acute pain

Dosage: TABLET;ORAL

How can I launch a generic of NUCYNTA before it's patent expiration?
More Information on Dosage

NUCYNTA family patents

15

United States

3

Norway

3

European Union

2

Denmark

2

Spain

2

Austria

2

Cyprus

2

Portugal

2

Poland

2

Germany

2

Slovenia

2

Argentina

2

Brazil

1

Ecuador

1

Australia

1

Israel

1

Croatia

1

Korea, Republic of

1

Canada

1

New Zealand

1

Peru

1

Russia

1

Japan

1

Mexico

1

China

1

South Africa

2. List of Nucynta Er drug patents

NUCYNTA ER's oppositions filed in EPO
NUCYNTA ER Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(9 months ago)

US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11007156 COLLEGIUM PHARM INC Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
Oct, 2022

(7 months ago)

US8309060 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(5 months from now)

US8420056 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(5 months from now)

US8075872 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(5 months from now)

US8114383 COLLEGIUM PHARM INC Abuse-proofed dosage form
Oct, 2024

(1 year, 4 months from now)

US11344512 COLLEGIUM PHARM INC Titration of tapentadol
Apr, 2028

(4 years from now)

US8536130 COLLEGIUM PHARM INC Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain
Sep, 2028

(5 years from now)

Do you want to check out NUCYNTA ER patents from before 2022?

Market Authorisation Date: 25 August, 2011

Treatment: Relief of moderate to severe chronic pain; Management of neuropathic pain associated with diabetic peripheral neuropathy; A method of titrating an opioid to manage pain severe enough to require daily,...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of NUCYNTA ER before it's patent expiration?
More Information on Dosage

NUCYNTA ER family patents

95

United States

29

European Union

17

Japan

15

Germany

14

Spain

14

Poland

14

Slovenia

13

Portugal

12

Denmark

11

Cyprus

11

Argentina

9

Croatia

9

Korea, Republic of

9

Canada

9

Hong Kong

9

China

8

Israel

8

Peru

8

Austria

8

Norway

7

Australia

7

Russia

7

Brazil

6

New Zealand

6

South Africa

5

Mexico

4

Ecuador

4

Hungary

2

Chile

2

Lithuania

1

Colombia

1

Malaysia

1

Taiwan

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in